论文部分内容阅读
目的:探讨并分析丙肝肝硬化患者的抗病毒治疗疗效。方法:选取我院于2014年1月-2015年10月间收治的60例丙肝肝硬化患者临床资料,其中34例处于代偿期,26例处于失代偿期,为两者提供利巴韦林与周派罗欣联合抗病毒治疗,前者剂量分别为600-1000mg/天、135-180μg/周,后者剂量分别为600-800mg/天、135μg/周,并随时根据患者病情进行药物剂量的调整。分别在12、24周时对于两组患者肝功能相关指标,以及患者的不良药物反应开展统计与分析。结果:与开展药物治疗之前相比,在治疗12周,患者临床疗效不显著(AST、TBIL、ALT及HCV RNA),P>0.05;在治疗24周,患者AST、TBIL、ALT及HCV RNA指标呈现明显改善,P<0.05。结论:根据丙肝肝硬化患者情况提供利巴韦林与周派罗欣联合抗病毒治疗,并有针对性的调节使用剂量对于改善患者肝脏功能,抑制病毒复制,从而缓解纤维化具有十分显著的疗效,值得临床推广。
Objective: To investigate and analyze the efficacy of antiviral therapy in patients with hepatitis C cirrhosis. Methods: The clinical data of 60 patients with hepatitis C cirrhosis who were treated in our hospital from January 2014 to October 2015 were selected. Among them, 34 patients were compensated and 26 patients were decompensated. Lin and Zhou Pei Luoxin combined antiviral therapy, the former doses were 600-1000mg / day, 135-180μg / week, the latter doses were 600-800mg / day, 135μg / week, and the patient’s condition at any time for the drug dose Adjustment. Statistics and analysis of liver function related indicators and adverse drug reactions of patients in two groups were performed at 12 and 24 weeks respectively. Results: Compared with those before drug treatment, the clinical efficacy was not significant (AST, TBIL, ALT and HCV RNA) at 12 weeks of treatment, P> 0.05. At 24 weeks, the AST, TBIL, ALT and HCV RNA Showed a significant improvement, P <0.05. Conclusion: According to the patients with hepatitis C cirrhosis ribavirin and the weekly Pegasys combined antiviral therapy, and targeted dose adjustment for improving the patient’s liver function, inhibition of viral replication, thereby reducing the fibrosis has a very significant effect , It is worth clinical promotion.